Leukocare, Trillium Partner on Sepsis Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – Leukocare and Trillium Diagnostics today announced a deal to develop and market Leukocare's method for detecting inflammatory activity using circulating cell-free DNA.

Trillium will use the method to develop a commercial assay for diagnosing sepsis, they said. Under the terms of the deal, Leukocare grants Trillium an exclusive, royalty-bearing license to its patent covering the technology and know-how for measuring the quantity of cf-DNA to develop a commercial in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.